Bryhali
Drugs - Bryhali™ (halobetasol propionate lotion) [Valeant Pharmaceuticals North America LLC]
August 2019
Therapeutic area - Steroids, Topical
Initial approval criteria
- Patient age ≥ 18 years of age AND
- Be prescribed by a dermatologist AND
- Patient has a diagnosis of moderate to severe plaque psoriasis AND
- Failed to adequately respond to at least one other high potency topical corticosteroid (e.g., betamethasone, clobetasol, fluocinonide, etc.) AND
- Failed to adequately respond to at least one oral treatment (cyclosporine, methotrexate)
- Patient does not have a history of allergic contact dermatitis with halobetasol propionate AND
- Halobetasol propionate lotion will be administered topically; it is not intended to be used orally, ophthalmically, or intravaginally or on the face, groin, or axillae AND
- Initial approval is for 2 fills (28-day supply per fill)
Renewal criteria
- Patient continues to be carefully monitored for adverse effects by a healthcare provider throughout the duration of treatment as documented in patient chart notes AND
- Patient has demonstrated clinical improvement in response to treatment as documented in patient chart notes
- Renewal approval is for 2 fills (28-day supply per fill)
Quantity limits
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411